Defining the critical hurdles in cancer immunotherapy

Fox, BA and Schendel, DJ and Butterfield, LH and Aamdal, S and Allison, JP and Ascierto, PA and Atkins, MB and Bartunkova, J and Bergmann, L and Berinstein, N and Bonorino, CC and Borden, E and Bramson, JL and Britten, CM and Cao, X and Carson, WE and Chang, AE and Characiejus, D and Raja Choudhury, A and Coukos, G and de Gruijl, T and Dillman, RO and Dolstra, H and Dranoff, G and Durrant, LG and Finke, JH and Galon, J and Gollob, JA and Gouttefangeas, C and Grizzi, F and Guida, M and Håkansson, L and Hege, K and Herberman, RB and Stephen Hodi, F and Hoos, A and Huber, C and Hwu, P and Imai, K and Jaffee, EM and Janetzki, S and June, CH and Kalinski, P and Kaufman, HL and Kawakami, K and Kawakami, Y and Keilholtz, U and Khleif, SN and Kiessling, R and Kotlan, B and Kroemer, G and Lapointe, R and Levitsky, HI and Lotze, MT and Maccalli, C and Maio, M and Marschner, JP and Mastrangelo, MJ and Masucci, G and Melero, I and Melief, C and Murphy, WJ and Nelson, B and Nicolini, A and Nishimura, MI and Odunsi, K and Ohashi, PS and O'Donnell-Tormey, J and Old, LJ and Ottensmeier, C and Papamichail, M and Parmiani, G and Pawelec, G and Proietti, E and Qin, S and Rees, R and Ribas, A and Ridolfi, R and Ritter, G and Rivoltini, L and Romero, PJ and Salem, ML and Scheper, RJ and Seliger, B and Sharma, P and Shiku, H and Singh-Jasuja, H and Song, W and Straten, PT and Tahara, H and Tian, Z and van der Burg, SH and von Hoegen, P and Wang, E and Welters, MJP and Winter, H and Withington, T and Wolchok, JD and Xiao, W and Zitvogel, L (2011) Defining the critical hurdles in cancer immunotherapy. Journal of Translational Medicine, 9 (1).

Preview	PDF Published Version Available under License : See the attached license file. Download (871kB) | Preview
	Plain Text (licence) Available under License : See the attached license file. Download (1kB)

Abstract

Scientific discoveries that provide strong evidence of antitumor effects in preclinical models often encounter significant delays before being tested in patients with cancer. While some of these delays have a scientific basis, others do not. We need to do better. Innovative strategies need to move into early stage clinical trials as quickly as it is safe, and if successful, these therapies should efficiently obtain regulatory approval and widespread clinical application. In late 2009 and 2010 the Society for Immunotherapy of Cancer (SITC), convened an "Immunotherapy Summit" with representatives from immunotherapy organizations representing Europe, Japan, China and North America to discuss collaborations to improve development and delivery of cancer immunotherapy. One of the concepts raised by SITC and defined as critical by all parties was the need to identify hurdles that impede effective translation of cancer immunotherapy. With consensus on these hurdles, international working groups could be developed to make recommendations vetted by the participating organizations. These recommendations could then be considered by regulatory bodies, governmental and private funding agencies, pharmaceutical companies and academic institutions to facilitate changes necessary to accelerate clinical translation of novel immune-based cancer therapies. The critical hurdles identified by representatives of the collaborating organizations, now organized as the World Immunotherapy Council, are presented and discussed in this report. Some of the identified hurdles impede all investigators; others hinder investigators only in certain regions or institutions or are more relevant to specific types of immunotherapy or first-in-humans studies. Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer. © 2011 Fox et al; licensee BioMed Central Ltd.

---

Share

Citation/Export:	Select format... Citation - Text Citation - HTML Endnote BibTex Dublin Core OpenURL MARC (ISO 2709) METS MODS EP3 XML Reference Manager Refer
Social Networking:	Share |

---

Details

Item Type:	Article
Status:	Published
Creators/Authors:	Creators Email Pitt Username ORCID Fox, BA Schendel, DJ Butterfield, LH lhb3@pitt.edu LHB3 Aamdal, S Allison, JP Ascierto, PA Atkins, MB Bartunkova, J Bergmann, L Berinstein, N Bonorino, CC Borden, E Bramson, JL Britten, CM Cao, X Carson, WE Chang, AE Characiejus, D Raja Choudhury, A Coukos, G de Gruijl, T Dillman, RO Dolstra, H Dranoff, G Durrant, LG Finke, JH Galon, J Gollob, JA Gouttefangeas, C Grizzi, F Guida, M Håkansson, L Hege, K Herberman, RB Stephen Hodi, F Hoos, A Huber, C Hwu, P Imai, K Jaffee, EM Janetzki, S June, CH Kalinski, P pak5@pitt.edu PAK5 Kaufman, HL Kawakami, K Kawakami, Y Keilholtz, U Khleif, SN Kiessling, R Kotlan, B Kroemer, G Lapointe, R Levitsky, HI Lotze, MT mtl5@pitt.edu MTL5 Maccalli, C Maio, M Marschner, JP Mastrangelo, MJ Masucci, G Melero, I Melief, C Murphy, WJ Nelson, B Nicolini, A Nishimura, MI Odunsi, K Ohashi, PS O'Donnell-Tormey, J Old, LJ Ottensmeier, C Papamichail, M Parmiani, G Pawelec, G Proietti, E Qin, S Rees, R Ribas, A Ridolfi, R Ritter, G Rivoltini, L Romero, PJ Salem, ML Scheper, RJ Seliger, B Sharma, P Shiku, H Singh-Jasuja, H Song, W Straten, PT Tahara, H Tian, Z van der Burg, SH von Hoegen, P Wang, E Welters, MJP Winter, H Withington, T Wolchok, JD Xiao, W Zitvogel, L
Centers:	Other Centers, Institutes, Offices, or Units > Pittsburgh Cancer Institute
Date:	14 December 2011
Date Type:	Publication
Journal or Publication Title:	Journal of Translational Medicine
Volume:	9
Number:	1
DOI or Unique Handle:	10.1186/1479-5876-9-214
Schools and Programs:	School of Medicine > Immunology School of Medicine > Medicine School of Medicine > Surgery
Refereed:	Yes
Date Deposited:	01 Nov 2016 17:03
Last Modified:	27 Apr 2019 14:55
URI:	http://d-scholarship.pitt.edu/id/eprint/29984

---

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com

---

Actions (login required)

View Item